[go: up one dir, main page]

PL2945642T3 - Białko czynnika 1 do zastosowania w leczeniu lub zapobieganiu chorobom - Google Patents

Białko czynnika 1 do zastosowania w leczeniu lub zapobieganiu chorobom

Info

Publication number
PL2945642T3
PL2945642T3 PL14700872.6T PL14700872T PL2945642T3 PL 2945642 T3 PL2945642 T3 PL 2945642T3 PL 14700872 T PL14700872 T PL 14700872T PL 2945642 T3 PL2945642 T3 PL 2945642T3
Authority
PL
Poland
Prior art keywords
protein
treating
factor
preventing diseases
diseases
Prior art date
Application number
PL14700872.6T
Other languages
English (en)
Inventor
Kai Christoph Wollert
Mortimer KORF-KLINGEBIEL
Original Assignee
Medizinische Hochschule Hannover
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Hochschule Hannover filed Critical Medizinische Hochschule Hannover
Publication of PL2945642T3 publication Critical patent/PL2945642T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
PL14700872.6T 2013-01-17 2014-01-16 Białko czynnika 1 do zastosowania w leczeniu lub zapobieganiu chorobom PL2945642T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13151593 2013-01-17
PCT/EP2014/050788 WO2014111458A2 (en) 2013-01-17 2014-01-16 Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases

Publications (1)

Publication Number Publication Date
PL2945642T3 true PL2945642T3 (pl) 2024-07-29

Family

ID=47559322

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14700872.6T PL2945642T3 (pl) 2013-01-17 2014-01-16 Białko czynnika 1 do zastosowania w leczeniu lub zapobieganiu chorobom

Country Status (17)

Country Link
US (1) US10369198B2 (pl)
EP (2) EP3747457A3 (pl)
JP (3) JP6809789B2 (pl)
CN (6) CN110894226A (pl)
CA (1) CA2898128A1 (pl)
DK (1) DK2945642T3 (pl)
ES (1) ES2986021T3 (pl)
FI (1) FI2945642T3 (pl)
HK (1) HK1215540A1 (pl)
HR (1) HRP20240623T1 (pl)
HU (1) HUE068364T2 (pl)
LT (1) LT2945642T (pl)
PL (1) PL2945642T3 (pl)
PT (1) PT2945642T (pl)
RS (1) RS65553B1 (pl)
SI (1) SI2945642T1 (pl)
WO (1) WO2014111458A2 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65553B1 (sr) * 2013-01-17 2024-06-28 Medizinische Hochschule Hannover Faktor 1 protein za upotrebu u lečenju ili prevenciji bolesti
CA2931309C (en) 2013-11-21 2022-06-21 The Brigham And Women's Hospital, Inc. Compositions and methods for treating pulmonary hypertension
WO2016019368A1 (en) * 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
US10435757B1 (en) 2016-06-15 2019-10-08 University Of South Florida Methods of measuring C19MC miRNA in a post-natal tissue and uses thereof
CN108802372B (zh) * 2018-06-19 2021-05-11 上海伦泽生物科技有限公司 检测人血清中内质网膜蛋白复合体亚单位10的试剂盒
PH12022551792A1 (en) 2020-01-21 2023-09-18 Boehringer Ingelheim Int Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure
CN114149499B (zh) * 2020-09-07 2023-12-05 复旦大学附属华山医院 抗人emc10的单克隆抗体及其在治疗和/或预防肥胖症中的应用
CN114149500B (zh) * 2020-09-07 2023-12-01 复旦大学附属华山医院 抗人emc10的单克隆抗体在制备治疗和/或预防脂肪肝的产品中的应用
CN114149498B (zh) * 2020-09-07 2023-12-05 复旦大学附属华山医院 抗人emc10的单克隆抗体在防治2型糖尿病中的应用
KR20230129245A (ko) 2020-12-23 2023-09-07 베링거 인겔하임 인터내셔날 게엠베하 심장 조직 세포에 특이성을 갖는 바이러스 캡시드 단백질
KR20240032971A (ko) * 2021-07-08 2024-03-12 테나야 테라퓨틱스, 인코포레이티드 유전자 요법을 위한 최적화된 발현 카세트
AU2023281912A1 (en) 2022-06-03 2024-12-12 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor
TW202426036A (zh) 2022-09-08 2024-07-01 德商百靈佳殷格翰國際有限公司 用於治療心因性休克的骨髓衍生性生長因子（二）
WO2025047991A1 (en) 2023-09-01 2025-03-06 Boehringer Ingelheim International Gmbh Myeloid-derived growth factor for use in treating or preventing a liver disorder

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
EP1009763A4 (en) 1996-06-11 2002-08-07 Merck & Co Inc SYNTHETIC GENES OF HEPATITIS C
JP2001506484A (ja) * 1996-09-13 2001-05-22 財団法人相模中央化学研究所 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ
EP0932676A2 (en) 1996-09-13 1999-08-04 Sagami Chemical Research Center HUMAN PROTEINS HAVING SECRETORY SIGNAL SEQUENCES AND DNAs ENCODING THESE PROTEINS
JP2001509168A (ja) * 1997-01-29 2001-07-10 コーネル リサーチ ファウンデーション、インコーポレイティッド 血管新生を誘導するためのアデノウイルスベクターの多部位送達
ES2371464T3 (es) 1999-05-26 2012-01-03 Next Biomed Technologies Nbt Oy Métodos y materiales para generar dominios sh3 con propiedades de unión seleccionadas.
PT1212417E (pt) * 1999-06-02 2008-07-29 Genentech Inc Promoção ou inibição de angiogénese e cardiovascularização
CA2381985A1 (en) * 1999-08-16 2001-02-22 Universita'degli Studi Di Siena Vegf-d and angiogenic use thereof
JP2004516013A (ja) * 2000-07-20 2004-06-03 ジェネンテック・インコーポレーテッド 血管形成に関連する障害を診断及び治療するための組成物と方法
WO2002081681A1 (fr) * 2001-03-30 2002-10-17 Chugai Seiyaku Kabushiki Kaisha Nouvelle utilisation de la cytokine sf20
DE10119804A1 (de) * 2001-04-23 2002-10-24 Brahms Ag Entzündungsspezifische Peptide und deren Verwendungen
WO2004060867A2 (en) * 2003-01-02 2004-07-22 Timothy Kirk Gallaher Secreted protein factor and cell membrane-bound splice variant
WO2004069173A2 (en) * 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
WO2005074836A1 (en) 2004-01-29 2005-08-18 Brown University Methods for progenitor cell recruitment and isolation
CN101160055A (zh) * 2005-02-16 2008-04-09 莱蒂恩公司 慢病毒载体及其用途
US20080004232A1 (en) * 2006-05-09 2008-01-03 John Wilkins Characterization of c19orf10, a Novel Synovial Protein
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
EP2130547A1 (en) * 2008-06-06 2009-12-09 Giuliani International Limited IL-25 for use in the treatment of inflammatory diseases
MX336152B (es) * 2009-08-29 2016-01-08 Abbvie Inc Proteinas terapeutico de union a dll4.
WO2011094446A1 (en) * 2010-01-27 2011-08-04 Neumedicines, Inc A method for treating brain cancer using a novel tumor suppressor gene and secreted factor
KR20120095063A (ko) * 2011-02-18 2012-08-28 가톨릭대학교 산학협력단 ＩＬ-27로 유도된 ｐ53을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
RS65553B1 (sr) * 2013-01-17 2024-06-28 Medizinische Hochschule Hannover Faktor 1 protein za upotrebu u lečenju ili prevenciji bolesti

Also Published As

Publication number Publication date
US20150352186A1 (en) 2015-12-10
CN111100197B (zh) 2024-11-15
RS65553B1 (sr) 2024-06-28
JP6809789B2 (ja) 2021-01-06
PT2945642T (pt) 2024-05-27
CN110894226A (zh) 2020-03-20
DK2945642T3 (da) 2024-05-27
LT2945642T (lt) 2024-06-25
CN104968361B (zh) 2019-12-17
JP2023025005A (ja) 2023-02-21
WO2014111458A2 (en) 2014-07-24
FI2945642T3 (fi) 2024-05-10
JP2020203894A (ja) 2020-12-24
HUE068364T2 (hu) 2024-12-28
JP2016506911A (ja) 2016-03-07
CN111100197A (zh) 2020-05-05
CN110903378A (zh) 2020-03-24
EP3747457A2 (en) 2020-12-09
US10369198B2 (en) 2019-08-06
CN104968361A (zh) 2015-10-07
WO2014111458A3 (en) 2014-09-12
ES2986021T3 (es) 2024-11-08
CN110922467A (zh) 2020-03-27
CN110922468A (zh) 2020-03-27
CA2898128A1 (en) 2014-07-24
SI2945642T1 (sl) 2024-07-31
HRP20240623T1 (hr) 2024-08-02
EP2945642B1 (en) 2024-02-21
EP2945642A2 (en) 2015-11-25
CN110922468B (zh) 2024-09-24
HK1215540A1 (zh) 2016-09-02
EP3747457A3 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
SI2945642T1 (sl) Protein faktorja 1 za uporabo pri zdravljenju ali preprečevanju bolezni
HK1216251A1 (zh) 吡唑並吡咯烷衍生物及其治病作用
HK1222552A1 (zh) 索布替羅用於治療髓鞘形成疾病
HK1222530A1 (zh) 用於皮膚處理的微閉合及相關方法
ZA201509369B (en) Insecticidal proteins and methods for their use
PL3010506T3 (pl) Pridopidyna w leczeniu choroby huntingtona
HK1220418A1 (zh) 治療呼吸系統疾病的方法及為此而製的製劑
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
PL3004112T3 (pl) Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
PL3466425T3 (pl) Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych
HK1224184A1 (zh) 用於治療炎性疾病的化合物、藥物組合物和方法
EP2978446A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
GB201511382D0 (en) Novel compounds and their use in therapy
HUE066502T2 (hu) Peptidek orális mucositis kezelésében történõ alkalmazásra
PL3041831T3 (pl) Postacie soli alfa-TEA: kompozycje i zastosowania do leczenia choroby
PL2943215T3 (pl) Peptydy pochodzące z laktoferycyny do zastosowania w leczeniu nowotworu
GB201308753D0 (en) Compounds and their use in therapy
GB2510477B (en) Formulations for use in the treatment of chronic fatigue and associated conditions, etc
EP3085710A4 (en) Protein and use thereof in treating multiple sclerosis
AP2015008849A0 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
GB201308217D0 (en) Compounds and their use in therapy
ZA201302565B (en) Methods for treating hyperuricemia and related diseases
GB201314623D0 (en) Novel mucinase for use in therapy or prophylaxis